Drugs / NanO2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06821347 | May 2025 → Jul 2026 overdue | ischemic stroke | NHS Greater Glasgow and Clyde | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT05389748 Comparator | Apr 2023 → Apr 2025 | ischemic stroke | NuvOx LLC | Unknown | No outcome recorded |
Press releases naming this drug 7 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NanO2 | “early administration of NanO2 in subjects with LVO ischemic stroke will maintain the viability of tissue in the penumbra until revascularization is achieved with intravenous...” NCT05389748 ↗ |
| Known as | NanO2TM | “Drug: NanO2TM” NCT06821347 ↗ |
| Modality | Other / unclassified | “Perfluorocarbon” NCT06821347 ↗ |
| Route | Intravenous | “A milky white intravenous injectable emulsion” NCT05389748 ↗ |